Brickell loses $13M on FDA prep, new drug platform
BOULDER — Brickell Biotech Inc. (Nasdaq: BBI) reported $100,000 in revenue for its third quarter and a loss of $13.3 million.
Revenue came from drug-licensing royalties in Japan. Losses, three times higher than in the same quarter last year, were driven by $10.2 million in research and development costs. It had $1.3 million in R&D in the third quarter of 2020.
General and administrative expenses stayed constant at about $3.3 million.
SPONSORED CONTENT
People Powered: Preparing Longmont Businesses for Economic Success
Longmont Chamber and FNBO present People Powered on April 24, 2024, aiming to inform business owners about workforce development, housing, and transportation issues.
The clinical stage pharmaceutical developer is gearing up for a new drug application to the U.S. Food and Drug Administration in mid-2022 for a gel said to reduce excessive sweating. Brickell spent $3.8 million on testing the gel in its third quarter.
It is also pursuing clinical testing of a second drug in Canada, for which it expects to report topline results by the end of next year.
Brickell reported cash and cash equivalents of $21.4 million as of Sept. 30, 2021, a decline of about 30% from the end of last year.
It replaced year-to-date cash burn with $8.9 million from an October public offering of common shares.
Brickell closed Tuesday at a $46 million market cap.
Pipeline
In the quarter, Brickell paid $2.5 million in cash and issued 2.8 million common shares at 89 cents a share to South Korea-based Voronoi Inc., a Securities and Exchange Commission filing said.
This is an initial payment for “exclusive, worldwide rights” to a proprietary platform Brickell will use to “research, develop and commercialize” new drugs for autoimmune and inflammatory diseases.Brickell will pay up to $318 million more to Voronoi as it develops drugs “contingent upon achievement of specified development, regulatory and commercial milestones,” the SEC filing said. Voronoi will also get up to 10% of net sales of products developed from the platform. All but $1 million in common stock of the commitment is for cash payments.